VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand therapies, proteolysis-targeting ...

Preterm birth can be severely harmful to neonates. Currently, no effective clinical treatments target in utero inflammation ...

Rhythm Pharmaceuticals, Inc. may be ripe in a year. At that time, setmelanotide should be approved for HO in the U.S. and ...

Gymnema sylvestre targets sugar receptors to reduce cravings while supporting pancreatic beta cell function. Bitter melon provides insulin-like activity, facilitating glucose transport into cells.